Walleye Capital’s 10x Genomics TXG Stock Holding History

Walleye Capital’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$506K	Buy	+13,200	New	+$346K	﹤0.01%	2732
2026 Q1	–	Sell	-5,800	Closed	-$94.6K	–	5004
2025 Q4	$94.6K	Buy	+5,800	New	+$87.6K	﹤0.01%	3898
2025 Q1	–	Sell	-1,300	Closed	-$18.7K	–	5157
2024 Q4	$18.7K	Sell	1,300 -7,300	-85%	-$115K	﹤0.01%	4514
2024 Q3	$194K	Sell	8,600 -42,500	-83%	-$879K	﹤0.01%	4029
2024 Q2	$994K	Buy	51,100 +50,400	+7,200%	+$1.32M	﹤0.01%	2855
2024 Q1	$26.3K	Sell	700 -4,700	-87%	-$207K	﹤0.01%	4852
2023 Q4	$302K	Sell	5,400 -500	-8%	-$21.8K	﹤0.01%	3364
2023 Q3	$243K	Sell	5,900 -3,000	-34%	-$156K	﹤0.01%	3399
2023 Q2	$497K	Buy	8,900 +6,700	+305%	+$363K	﹤0.01%	2445
2023 Q1	$123K	Sell	2,200 -3,600	-62%	-$168K	﹤0.01%	2814
2022 Q4	$211K	Buy	+5,800	New	+$190K	﹤0.01%	2009

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Walleye Capital's TXG Position: Q2 2026 in Review

Walleye Capital opened a new position in 10x Genomics (TXG) in Q2 2026: 100 shares worth $3.83K. The stake represents ﹤0.01% of the portfolio and ranks #4556 among its holdings. This is a return to the name: Walleye Capital previously reported a position in TXG as recently as Q4 2025.

Walleye Capital first reported a position in TXG in Q2 2020 and has held it in 14 quarters since. The position peaked at $4.19M in Q4 2024. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Walleye Capital held 100 shares of 10x Genomics worth $3.83K as of Q2 2026.
10x Genomics was a new Walleye Capital position in Q2 2026.
10x Genomics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4556 holding.
Walleye Capital first reported a position in 10x Genomics in Q2 2020 and has held it in 14 quarters since.
Walleye Capital's 10x Genomics position peaked at $4.19M in Q4 2024.
392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.